These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 22087362)

  • 1. Effect of Shifting from Combination Therapy to Monotherapy of α-Blockers or 5α-Reductase Inhibitors on Prostate Volume and Symptoms in Patients with Benign Prostatic Hyperplasia.
    Kim HW; Moon DG; Kim HM; Hwang JH; Kim SC; Nam SG; Park JT
    Korean J Urol; 2011 Oct; 52(10):681-6. PubMed ID: 22087362
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Influence of baseline variables on changes in International Prostate Symptom Score after combined therapy with dutasteride plus tamsulosin or either monotherapy in patients with benign prostatic hyperplasia and lower urinary tract symptoms: 4-year results of the CombAT study.
    Roehrborn CG; Barkin J; Tubaro A; Emberton M; Wilson TH; Brotherton BJ; Castro R
    BJU Int; 2014 Apr; 113(4):623-35. PubMed ID: 24127818
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Monotherapy versus combination drug therapy for the treatment of benign prostatic hyperplasia.
    Logan YT; Belgeri MT
    Am J Geriatr Pharmacother; 2005 Jun; 3(2):103-14. PubMed ID: 16129387
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adding Cyclooxygenase-2 inhibitor to alpha blocker for patients with benign prostate hyperplasia and elevated serum prostate specific antigen could not improve prostate biopsy detection rate but improve lower urinary tract symptoms.
    Jhang JF; Jiang YH; Kuo HC
    Int J Clin Pract; 2013 Dec; 67(12):1327-33. PubMed ID: 24246211
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A review of combination therapy in patients with benign prostatic hyperplasia.
    McVary KT
    Clin Ther; 2007 Mar; 29(3):387-98. PubMed ID: 17577460
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The role of combination medical therapy in benign prostatic hyperplasia.
    Greco KA; McVary KT
    Int J Impot Res; 2008 Dec; 20 Suppl 3():S33-43. PubMed ID: 19002123
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of Finasteride (5 alpha-reductase inhibitor) monotherapy in patients with benign prostatic hyperplasia: A critical review of the literature.
    Busetto GM; Del Giudice F; D'Agostino D; Romagnoli D; Minervini A; Rocco B; Antonelli A; Celia A; Schiavina R; Cindolo L; Chung BI; Kim JH; Maggi M; Sciarra A; De Berardinis E; Porreca A
    Arch Ital Urol Androl; 2020 Jan; 91(4):205-210. PubMed ID: 31937082
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Comparison of different drugs on the treatment of benign prostate hyperplasia].
    Li NC; Wu SL; Jin J; Qiu SP; Kong CZ; Song YS; Ye ZQ; Sun G; Sun YH; Sun YC; Wang XF; Na YQ
    Zhonghua Wai Ke Za Zhi; 2007 Jul; 45(14):947-50. PubMed ID: 17961376
    [TBL] [Abstract][Full Text] [Related]  

  • 9. 5α-Reductase inhibitor is less effective in men with small prostate volume and low serum prostatic specific antigen level.
    Lin VC; Liao CH; Wang CC; Kuo HC
    J Formos Med Assoc; 2015 Sep; 114(9):865-71. PubMed ID: 24064231
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of α-blocker monotherapy and α-blocker plus 5α-reductase inhibitor combination therapy based on prostate volume for treatment of benign prostatic hyperplasia.
    Joo KJ; Sung WS; Park SH; Yang WJ; Kim TH
    J Int Med Res; 2012; 40(3):899-908. PubMed ID: 22906262
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A retrospective study of clinical outcomes of α-blocker or finasteride monotherapy followed by combination therapy: determination of the period of combination therapy of α-blocker and finasteride.
    Son H; Cho SY; Park S; Kang JY; Kim CS; Kim HG
    Int J Clin Pract; 2013 Apr; 67(4):351-5. PubMed ID: 23521327
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The influence of baseline parameters on changes in international prostate symptom score with dutasteride, tamsulosin, and combination therapy among men with symptomatic benign prostatic hyperplasia and an enlarged prostate: 2-year data from the CombAT study.
    Roehrborn CG; Siami P; Barkin J; Damião R; Becher E; Miñana B; Mirone V; Castro R; Wilson T; Montorsi F;
    Eur Urol; 2009 Feb; 55(2):461-71. PubMed ID: 19013011
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prospective factor analysis of alpha blocker monotherapy failure in benign prostatic hyperplasia.
    Hong KP; Byun YJ; Yoon H; Park YY; Chung WS
    Korean J Urol; 2010 Jul; 51(7):488-91. PubMed ID: 20664783
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical outcomes after combined therapy with dutasteride plus tamsulosin or either monotherapy in men with benign prostatic hyperplasia (BPH) by baseline characteristics: 4-year results from the randomized, double-blind Combination of Avodart and Tamsulosin (CombAT) trial.
    Roehrborn CG; Barkin J; Siami P; Tubaro A; Wilson TH; Morrill BB; Gagnier RP
    BJU Int; 2011 Mar; 107(6):946-54. PubMed ID: 21332630
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy of Adding Dutasteride to α-Blocker Therapy Treated Benign Prostatic Hyperplasia Patients with Small Volume Prostate (<30 mL).
    Hashimoto M; Shimizu N; Sugimoto K; Hongoh S; Minami T; Nozawa M; Yoshimura K; Hirayama A; Tahara H; Uemura H
    Low Urin Tract Symptoms; 2017 Sep; 9(3):157-160. PubMed ID: 26991643
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Transitional Zone Index as a Predictor of the Efficacy of α-Blocker and 5α-Reductase Inhibitor Combination Therapy in Korean Patients with Benign Prostatic Hyperplasia.
    Choi JD; Kim JH; Ahn SH
    Urol Int; 2016; 96(4):406-12. PubMed ID: 26824527
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and tolerability of doxazosin and finasteride, alone or in combination, in treatment of symptomatic benign prostatic hyperplasia: the Prospective European Doxazosin and Combination Therapy (PREDICT) trial.
    Kirby RS; Roehrborn C; Boyle P; Bartsch G; Jardin A; Cary MM; Sweeney M; Grossman EB;
    Urology; 2003 Jan; 61(1):119-26. PubMed ID: 12559281
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ultrasound image features of intravesical prostatic protrusion indicated failure of medication therapy of finasteride and doxazosin in patients with benign prostatic hyperplasia (LUTS/BPH).
    Liu Q; Zhu Y; Liu J; Qi J; Kang J
    Int Urol Nephrol; 2017 Mar; 49(3):399-404. PubMed ID: 27987130
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of dutasteride, tamsulosin and the combination on patient-reported quality of life and treatment satisfaction in men with moderate-to-severe benign prostatic hyperplasia: 4-year data from the CombAT study.
    Montorsi F; Henkel T; Geboers A; Mirone V; Arrosagaray P; Morrill B; Black L
    Int J Clin Pract; 2010 Jul; 64(8):1042-51. PubMed ID: 20487046
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Cardura monotherapy versus combination therapy of cardura and tolterodine L-tartrate tablets for II° ? benign prostatic hyperplasia with overactive bladder].
    Wang YY; Shi GW; He JY; Zhang YB
    Zhonghua Nan Ke Xue; 2013 Dec; 19(12):1099-102. PubMed ID: 24432622
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.